Valneva SE (NASDAQ:VALN) Sees Large Decline in Short Interest

Valneva SE (NASDAQ:VALN) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 5,800 shares, a drop of 84.2% from the February 13th total of 36,700 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 59,500 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new stake in Valneva SE (NASDAQ:VALN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Stock Up 0.2 %

NASDAQ VALN traded up $0.02 on Wednesday, hitting $7.08. 3,080 shares of the stock were exchanged, compared to its average volume of 25,708. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The company has a 50-day moving average price of $5.97 and a 200-day moving average price of $5.61. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $574.92 million, a PE ratio of -54.65 and a beta of 1.93.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Valneva in a research report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.